FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:972-973 September 28, 2000 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Singhal, S. PubMed Citation

To the Editor: Thalidomide has recently been shown to be effective for the treatment of refractory myeloma.^1,2 We report a case of life-threatening toxic epidermal necrolysis with the combined use of thalidomide and dexamethasone in a patient with previously untreated myeloma.

A 64-year-old man with newly diagnosed myeloma presented with multiple lytic bone lesions, anemia, and hypercalcemia, with a serum IgA-lambda monoclonal protein level of 41 g per liter and 90 percent plasma cells in the bone marrow. After obtaining informed consent, we initiated treatment with thalidomide and dexamethasone as part of an ongoing phase 2 trial. The patient received . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., Boccadoro, M., Harousseau, J.-L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111: 3968-3977 [Abstract] [Full Text]  
• Fonseca, R., Stewart, A. K. (2007). Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. Molecular Cancer Therapeutics 6: 802-810 [Abstract] [Full Text]  
• Saunders, G. (2005). Overview of drug therapy for multiple myeloma. J Oncol Pharm Pract 11: 83-100 [Abstract]  
• Maurer, T., Poncelet, A., Berger, T. (2004). Thalidomide Treatment for Prurigo Nodularis in Human Immunodeficiency Virus-Infected Subjects: Efficacy and Risk of Neuropathy. Arch Dermatol 140: 845-849 [Abstract] [Full Text]  
• Rajkumar, S. V. (2004). Thalidomide: Tragic Past and Promising Future. Mayo Clin Proc. 79: 899-903  
• Kumar, S., Witzig, T. E., Rajkumar, S. V. (2004). Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies. JCO 22: 2477-2488 [Abstract] [Full Text]  
• Remlinger, K. A. (2003). Cutaneous Reactions to Chemotherapy Drugs: The Art of Consultation. Arch Dermatol 139: 77-81 [Full Text]  
• Kumar, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Geyer, S. M., Iturria, N. L., Fonseca, R., Hayman, S. R., Lust, J. A., Kyle, R. A., Greipp, P. R., Witzig, T. E., Rajkumar, S. V. (2003). Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. Mayo Clin Proc. 78: 34-39 [Abstract]  
• Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., Kyle, R. A., Witzig, T. E. (2002). Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. JCO 20: 4319-4323 [Abstract] [Full Text]  
• Neben, K., Moehler, T., Benner, A., Kraemer, A., Egerer, G., Ho, A. D., Goldschmidt, H. (2002). Dose-dependent Effect of Thalidomide on Overall Survival in Relapsed Multiple Myeloma. Clin. Cancer Res. 8: 3377-3382 [Abstract] [Full Text]  
• Vincent Rajkumar, S., Kyle, R. A. (2001). Thalidomide in the Treatment of Plasma Cell Malignancies. JCO 19: 3593-3595 [Full Text]  
• Osman, K., Comenzo, R., Rajkumar, S. V. (2001). Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma. NEJM 344: 1951-1952 [Full Text]